.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Medtronic recently announced its plans to buy SPR Therapeutics for $650 million. This strategic move aims to expand non-opioid options for chronic pain management. Consequently, healthcare providers will gain earlier access to minimally invasive therapies. Furthermore, this acquisition enhances Medtronic's extensive neuromodulation portfolio.
Chronic pain affects millions of individuals globally and severely impacts their quality of life. Traditional interventions often rely on invasive surgeries or potentially addictive opioid prescriptions. However, clinical demand is rapidly shifting toward safer and less invasive alternatives. Therefore, the medical community actively seeks temporary solutions that bridge the gap in patient care. This transaction addresses that exact need by offering a non-permanent neurostimulation option.
The acquisition centers on SPR Therapeutics' FDA-cleared SPRINT Peripheral Nerve Stimulation (PNS) System. Specifically, this innovative device delivers a percutaneous, 60-day temporary treatment. Moreover, it does not require a permanent surgical implant. In addition, real-world clinical data involving over 6,100 patients demonstrated significant success. Specifically, more than 71% of patients reported remarkable pain relief and improved quality of life. Consequently, clinicians can deploy this system much earlier in the patient’s treatment plan.
Medtronic plans to complete this cash transaction in the first half of its fiscal year 2027. Currently, the deal is subject to standard regulatory approvals and customary closing conditions. Until the deal officially closes, both companies will continue to operate as separate entities. Additionally, this purchase represents Medtronic's third major medical technology acquisition this year. Ultimately, this strategic expansion highlights Medtronic's strong commitment to advancing patient-centered neuromodulation technologies.
Q1: What is the SPRINT PNS System?
The SPRINT PNS System is an FDA-cleared, temporary peripheral nerve stimulation device. Specifically, it delivers a short-term, 60-day therapy to provide significant pain relief without requiring a permanent surgical implant.
Q2: Why did Medtronic decide to acquire SPR Therapeutics?
Medtronic acquired the company to expand its chronic pain management portfolio. Consequently, this acquisition allows Medtronic to offer earlier, less invasive, and non-opioid pain relief options to patients.
Q3: When is the acquisition of SPR Therapeutics expected to close?
The transaction is expected to close in the first half of Medtronic's fiscal year 2027. However, this timeline is subject to customary regulatory approvals.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Medtronic has announced its plans to acquire SPR Therapeutics for $650 million, expanding its non-opioid, minimally invasive chronic pain treatments....
3 months ago
A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
